Centogene NV logo

CNTG - Centogene NV Share Price

$12.17 0.3  2.5%

Last Trade - 30/10/20

Sector
Healthcare
Size
Mid Cap
Market Cap £392.4m
Enterprise Value £401.2m
Revenue £43.8m
Position in Universe 2867th / 6399
Bullish
Bearish
Unlock CNTG Revenue
Momentum
Relative Strength (%)
1m +31.4%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -57.6%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 27.7 31.7 40.5 48.8 65.0 67.7 +20.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, Centogene NVrevenues decreased less than 1% to EUR21.8M. Net lossincreased 65% to EUR19.1M. Revenues reflect Diagnosticssegment increase from EUR6.6M to EUR13.3M, Pharmaceuticalsegment increase from EUR4.1M to EUR8.5M, United Statessegment increase from EUR4.5M to EUR9.3M, Saudi Arabiasegment increase from EUR1.7M to EUR4.1M, also reflectNorth America segment decrease of 42% to EUR157K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

CNTG Revenue Unlock CNTG Revenue

Net Income

CNTG Net Income Unlock CNTG Revenue

Normalised EPS

CNTG Normalised EPS Unlock CNTG Revenue

PE Ratio Range

CNTG PE Ratio Range Unlock CNTG Revenue

Dividend Yield Range

CNTG Dividend Yield Range Unlock CNTG Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
CNTG EPS Forecasts Unlock CNTG Revenue
Profile Summary

Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion weighted data points from over 450,000 patients representing around 115 different, which includes epidemiologic, phenotypic and genetic data that reflects a global population, as well as a biobank of patients’ blood samples. In addition, it is active in the research and development products for human genetics. The Company operates in Germany and the United States.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated October 11, 2018
No. of Shareholders: 20
No. of Employees: 442
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 21,861,340
Free Float (0.0%)
Eligible for
ISAs
SIPPs
CNTG Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for CNTG
Upcoming Events for CNTG
Thursday 3rd December, 2020 Estimate
Q3 2020 Centogene NV Earnings Release
Wednesday 21st April, 2021 Estimate
Q4 2020 Centogene NV Earnings Release
Frequently Asked Questions for Centogene NV
What is the Centogene NV share price?

As of 30/10/20, shares in Centogene NV are trading at $12.17, giving the company a market capitalisation of £392.4m. This share price information is delayed by 15 minutes.

How has the Centogene NV share price performed this year?

Shares in Centogene NV are currently trading at $12.17 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Centogene NV price has moved by % over the past year.

What are the analyst and broker recommendations for Centogene NV?

There are no analysts currently covering Centogene NV.

When will Centogene NV next release its financial results?

Centogene NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Centogene NV dividend yield?

Centogene NV does not currently pay a dividend.

Does Centogene NV pay a dividend?

Centogene NV does not currently pay a dividend.

When does Centogene NV next pay dividends?

Centogene NV does not currently pay a dividend.

How do I buy Centogene NV shares?

To buy shares in Centogene NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Centogene NV?

Shares in Centogene NV are currently trading at $12.17, giving the company a market capitalisation of £392.4m.

Where are Centogene NV shares listed? Where are Centogene NV shares listed?

Here are the trading details for Centogene NV:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: CNTG
What kind of share is Centogene NV?

Based on an overall assessment of its quality, value and momentum, Centogene NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Centogene NV share price forecast 2020?

Shares in Centogene NV are currently priced at $12.17. At that level they are trading at 55.88% discount to the analyst consensus target price of 0.00.

Analysts covering Centogene NV currently have a consensus Earnings Per Share (EPS) forecast of -1.5450989954 for the next financial year.

How can I tell whether the Centogene NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Centogene NV. Over the past six months, the relative strength of its shares against the market has been -44.61%. At the current price of $12.17, shares in Centogene NV are trading at -17.77% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Centogene NV PE Ratio?

We were not able to find PE ratio data for Centogene NV.

Who are the key directors of Centogene NV?

Centogene NV's management team is headed by:

Arndt Rolfs - CEO
Peter Bauer - OTH
Richard Stoffelen - CFO
Volkmar Weckesser - CIO
Flemming Ornskov - CSU
Hubert Birner - IND
Dirk Ehlers - COO
Oved Amitay - OTH
Sun Kim - DIR
Philip Lambert - CSO
Peer Schatz - VSU
Christoph Ehlers - SUB
Guido Prehn - IND
Eric Souetre - IND
Berndt Modig - IND
Who are the major shareholders of Centogene NV?

Here are the top five shareholders of Centogene NV based on the size of their shareholding:

DPE Deutsche Private Equity GmbH Private Equity
Percentage owned: 23.44% (5.12m shares)
Careventures S.A. Corporation
Percentage owned: 14.86% (3.25m shares)
TVM Capital GmbH Venture Capital
Percentage owned: 12.77% (2.79m shares)
Rolfs (Arndt M.D.) Individual Investor
Percentage owned: 11.03% (2.41m shares)
Equicore Beteiligungs GmbH Corporation
Percentage owned: 8.47% (1.85m shares)
Similar to CNTG
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.